Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
35,36 For example, patients with TIF1 autoantibodies tend to have skin-predominant, amyopathic disease and are less likely to have Raynauds phenomenon and arthralgias/arthritis compared to other DM patients
It is known that insulin is involved in neuronal survival, synaptic plasticity, memory, and cognitive function in the central nervous system (CNS), and existing hypotheses suggest that similar to diabetic neuropathy, impaired insulin signalling pathways due to elevated blood glucose and lipids may be the main metabolic mechanism that induces the occurrence of diabetic cognitive dysfunction (6)
What is PT-141 (bremelanotide) and how does it work for men PT-141 is a melanocortin receptor agonist that enhances sexual function through brain pathways
In addition to inferring WM integrity, DTI can also be applied to reconstruct cerebral WM tracts
Glutamine, serine, and glycine have been identified to function as metabolic regulators in supporting cancer cell growth (60)
